Cluster Headache and Migraine: Definition, Mechanisms, and Clinical Spectrum
Cluster headache is a primary trigeminal autonomic cephalalgia characterized by severe unilateral periocular pain lasting 15 to 180 minutes. It is accompanied by ipsilateral cranial autonomic symptoms such as lacrimation, rhinorrhea, and ptosis (Holle Lee and Gaul, 2016).
Both disorders share a common foundation in activation of the trigeminovascular system, which mediates nociceptive signaling and contributes to neuropeptide release and neuroinflammation.
Clinically, cluster headache is noted for its extreme pain intensity and circadian rhythmicity. There is frequent misdiagnosis, particularly in women, due to overlapping migraine-like symptoms (Goadsby et al., 2025).
Why Vagus Nerve Stimulation for Cluster Headache and Migraine
Understanding Headache Types: Cluster and Migraine
Vagus nerve stimulation has emerged as a promising neuromodulatory strategy for both cluster headache and migraine because these disorders share pathophysiological mechanisms that are strongly influenced by vagal afferent input.
Clinical evidence shows that noninvasive vagus nerve stimulation modulates trigeminal allodynia, reduces glutamatergic activity in the trigeminal nucleus caudalis, and produces antinociceptive effects in both preclinical and human studies (Holle Lee and Gaul, 2016).
In cluster headache specifically, the trigeminal–autonomic reflex is a defining mechanism. VNS attenuates parasympathetic overactivation and can modulate cranial autonomic symptoms.
Noninvasive approaches also address the limitations of implanted devices by avoiding surgical risks while offering high tolerability and favorable safety profiles. Systematic reviews highlight that transcutaneous VNS yields mainly mild, transient adverse effects without increased risk compared to control conditions (Kim et al., 2022).
Together, these mechanistic and clinical data position vagus nerve stimulation as a targeted, safe, and biologically grounded treatment option for patients with migraine and cluster headache whose disease reflects dysfunction across vagally mediated pain and autonomic pathways.
Vagus Nerve Stimulation Procedure & Targets in Cluster Headache and Migraine
Vagus nerve stimulation for cluster headache and migraine is delivered either invasively through surgically implanted cervical electrodes or noninvasively using transcutaneous stimulation devices designed to activate the cervical or auricular branches of the vagus nerve.
In cluster headache, the therapeutic target is the trigeminal–autonomic reflex arc. Stimulation of cervical vagal afferents can counteract parasympathetic overactivation and reduce cranial autonomic symptoms by altering signaling within the sphenopalatine and trigeminovascular pathways (Holle Lee and Gaul, 2016).
In migraine, VNS targets broader pain modulation circuits. Functional imaging studies demonstrate that VNS alters connectivity within default mode, vestibular, and limbic networks that are disrupted in migraineurs, particularly regions such as the inferior temporal gyrus, orbitofrontal cortex, and cerebellar lobules involved in pain processing and sensory integration (Rao et al., 2023).
The transcutaneous auricular approach stimulates the auricular branch of the vagus nerve at the tragus or concha. Although anatomically distinct from cervical stimulation, this method similarly engages the nucleus tractus solitarius and downstream antinociceptive circuits, while avoiding unintended activation of efferent cardiac fibers (Kim et al., 2022).
Clinical Outcomes & Long-Term Efficacy of VNS in Cluster Headache and Migraine
Vagus nerve stimulation has demonstrated clinically meaningful benefits for people living with cluster headache and migraine. It offers both rapid relief during attacks and sustained reductions in headache burden over time.
In migraine, VNS has demonstrated benefits across several key outcomes: fewer monthly headache days, shorter attacks, and lower overall pain intensity.
Auricular stimulation provides further evidence for migraine relief. Studies show reduced attack duration and frequency, accompanied by modulation of brainstem and thalamocortical pathways central to migraine pathophysiology (Rao et al., 2023).
Taken together, these findings demonstrate that VNS is not simply an alternative to medication but a clinically validated neuromodulation tool capable of delivering meaningful, durable improvements in both cluster headache and migraine.
Side Effects & Safety Profile
Vagus nerve stimulation is considered a highly safe and well-tolerated neuromodulation option for both cluster headache and migraine. Across clinical studies, noninvasive VNS consistently shows a side-effect profile that is mild, transient, and comparable to placebo, making it one of the safest therapeutic tools available in headache management.
Large-scale safety analyses reinforce these findings. A systematic review evaluating more than six thousand participants undergoing transcutaneous vagus nerve stimulation found no increased risk of serious adverse events, and importantly, no causal relationship between VNS and major cardiac, respiratory, or neurological complications (Kim et al., 2022).
For auricular VNS, the safety profile remains similarly favorable. Reported effects such as mild ear discomfort or temporary skin irritation are rare and self-limited, further supporting the method’s feasibility for long-term preventive use (Kim et al., 2022).
Overall, the available evidence demonstrates that VNS offers a strong balance of efficacy and safety, enabling patients to pursue meaningful headache relief without the burden of significant side effects.
What to Expect During Recovery and Follow-Up
Recovery and follow-up after starting vagus nerve stimulation are typically smooth, as the therapy does not require surgery and users can begin applying sessions immediately.
For individuals treating cluster headache, relief during acute attacks may appear rapidly, sometimes within minutes.
Follow-up visits play an essential role in maintaining long-term efficacy. These appointments typically involve reviewing symptom patterns, fine-tuning stimulation schedules, and ensuring the technique is being applied correctly.
Most patients integrate stimulation seamlessly into their daily routines, whether using VNS as a stand-alone tool or alongside medications and behavioral strategies.
Predictors of Successful VNS Outcomes
Several patient and disease characteristics appear to influence how well individuals respond to vagus nerve stimulation for cluster headache and migraine.
Another factor consistently associated with successful outcomes is early symptom responsiveness. Individuals who experience noticeable reductions in pain intensity or attack duration during the first weeks of use tend to maintain long-term benefit. This pattern likely reflects more efficient engagement of the vagus nerve’s afferent pathways and more adaptable central pain networks (Holle Lee & Gaul, 2016). Imaging studies strengthen this concept: patients showing early normalization of functional connectivity in sensory and limbic circuits also report greater improvement in headache burden (Rao et al., 2023).
Another factor consistently associated with successful outcomes is early symptom responsiveness. Individuals who experience noticeable reductions in pain intensity or attack duration during the first weeks of use tend to maintain long-term benefit.
Consistency of use is equally important. Regular stimulation sessions appear to enhance cumulative neuromodulatory effects, particularly in migraine, where long-term improvements correlate with ongoing modulation of pain-processing networks and autonomic regulation (Goadsby et al., 2025).
Overall, favorable predictors of VNS success include episodic disease patterns, early clinical improvement, consistent treatment adherence, and proper stimulation technique.
Summary
Vagus nerve stimulation has emerged as a versatile and clinically meaningful treatment option for individuals living with cluster headache and migraine.
In cluster headache, stimulation has been shown to reduce attack intensity rapidly while also lowering weekly attack frequency when used preventively.
Safety remains one of the strongest advantages of VNS. Large-scale analyses of transcutaneous stimulation confirm a low incidence of adverse events, with side effects generally limited to brief local sensations such as tingling or mild skin irritation.
Predicting success with VNS often depends on several clinical factors. Individuals with episodic headache patterns, early symptom responsiveness, and consistent adherence to stimulation schedules typically experience the most robust outcomes. Proper device technique, especially in auricular approaches, further enhances effectiveness (Goadsby et al., 2025).
Taken together, the evidence across mechanistic research, clinical outcomes, and safety data positions vagus nerve stimulation as a highly promising therapy for both cluster headache and migraine.
References
Goadsby, P. J., Feoktistov, A., Anitescu, M., Day, M., & Staats, P. (2025). Non-invasive vagus nerve stimulation in cluster headache: A clinical practice guideline. Pain Practice, 25, e70084.
Holle-Lee, D., & Gaul, C. (2016). Noninvasive vagus nerve stimulation in the management of cluster headache: Clinical evidence and practical experience. Therapeutic Advances in Neurological Disorders, 9(3), 230–234.
Hord, E. D., Evans, M. S., Mueed, S., Adamolekun, B., & Naritoku, D. K. (2003). The effect of vagus nerve stimulation on migraines. The Journal of Pain, 4(9), 530–534.
Kim, A. Y., Marduy, A., de Melo, P. S., Gianlorenco, A. C., Kim, C. K., Choi, H., Song, J.-J., & Fregni, F. (2022). Safety of transcutaneous auricular vagus nerve stimulation: A systematic review and meta-analysis. Scientific Reports, 12, 22055.
Lendvai, I. S., Maier, A., Scheele, D., Hurlemann, R., & Kinfe, T. M. (2018). Spotlight on cervical vagus nerve stimulation for the treatment of primary headache disorders: A review. Journal of Pain Research, 11, 1613–1625.
Magis, D., Gérard, P., & Schoenen, J. (2013). Transcutaneous vagus nerve stimulation for headache prophylaxis: Initial experience. The Journal of Headache and Pain, 14(Suppl 1), P198.
Rao, Y., Liu, W., Zhu, Y., Lin, Q., Kuang, C., Huang, H., Jiao, B., Ma, L., & Lin, J. (2023). Altered functional brain network patterns in patients with migraine without aura after transcutaneous auricular vagus nerve stimulation. Scientific Reports, 13, 9604.
Headache